Search

Brenda Lynn Palucki

age ~53

from Collegeville, PA

Also known as:
  • Brenda L Palucki
  • Brenda L Gacek
Phone and address:
33 Longacre Dr, Collegeville, PA 19426
610 489-5796

Brenda Palucki Phones & Addresses

  • 33 Longacre Dr, Collegeville, PA 19426 • 610 489-5796
  • 3 Horseshoe Dr, Hillsborough, NJ 08844 • 908 431-0154
  • Basking Ridge, NJ
  • Somerville, MA
  • Belle Mead, NJ
  • San Diego, CA
  • Cambridge, MA
  • Orland Hills, IL
  • 33 Longacre Dr, Collegeville, PA 19426 • 908 431-0154

Work

  • Position:
    Professional/Technical

Education

  • Degree:
    Associate degree or higher

Us Patents

  • Substituted Piperidines As Melanocortin-4 Receptor Agonists

    view source
  • US Patent:
    6350760, Feb 26, 2002
  • Filed:
    Jun 1, 2000
  • Appl. No.:
    09/585111
  • Inventors:
    Raman K. Bakshi - Edison NJ
    Khaled J. Barakat - Brooklyn NY
    Ravi P. Nargund - East Brunswick NJ
    Brenda L. Palucki - Belle Mead NJ
    Arthur A. Patchett - Westfield NJ
    Iyassu Sebhat - Hoboken NJ
    Zhixiong Ye - Princeton NJ
    Leonardus H. T. Van Der Ploeg - Scotch Plains NJ
  • Assignee:
    Merck Co., Inc. - Rahway NJ
  • International Classification:
    A61K 3144
  • US Classification:
    514323, 51421016, 51421304, 514307, 540200, 540476, 540593, 540594, 546146, 546200, 546201
  • Abstract:
    Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Also provided are methods of treating sexual dysfunction with a compound that is a selective agonist of MC-4R over any other human melanocortin receptor.
  • Spiropiperidine Derivatives As Melanocortin Receptor Agonists

    view source
  • US Patent:
    6410548, Jun 25, 2002
  • Filed:
    Feb 12, 2001
  • Appl. No.:
    09/781373
  • Inventors:
    Ravi P. Nargund - East Brunswick NJ
    Zhixiong Ye - Lawrenceville NJ
    Brenda L. Palucki - Belle Mead NJ
    Raman K. Bakshi - Edison NJ
    Arthur A. Patchett - Westfield NJ
    Leonardus H. T. Van Der Ploeg - Scotchplains NJ
  • Assignee:
    Merck Co., Inc. - Rahway NJ
  • International Classification:
    A61K 31438
  • US Classification:
    514278, 514315, 514317, 546 18, 546 17, 546122
  • Abstract:
    Certain novel spiropiperidine compounds are agonists of melanocortin receptor(s) and are useful for the treatment, control or prevention of diseases and disorders responsive to the activation of melanocortin receptors. The compounds of the present invention are therefore useful for treatment of diseases and disorders such as obesity, diabetes, sexual dysfunction including erectile dysfunction and female sexual dysfunction.
  • Substituted Piperidines As Melanocortin Receptor Agonists

    view source
  • US Patent:
    6458790, Oct 1, 2002
  • Filed:
    Mar 20, 2001
  • Appl. No.:
    09/812965
  • Inventors:
    Brenda L. Palucki - Hillsborough NJ
    Khaled J. Barakat - Brooklyn NY
    Liangqin Guo - Edison NJ
    Yingjie Lai - Edison NJ
    Ravi P. Nargund - East Brunswick NJ
    Min K. Park - Whippany NJ
    Patrick G. Pollard - Oakhurst NJ
    Iyassu K. Sebhat - Hoboken NJ
    Zhixiong Ye - Princeton NJ
  • Assignee:
    Merck Co., Inc. - Rahway NJ
  • International Classification:
    C07D40112
  • US Classification:
    5142372, 5142278, 5142322, 51425309, 5142531, 51425313, 544 60, 544 61, 544 96, 544120, 544122, 544130, 544360, 544364, 544365
  • Abstract:
    Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment and control of obesity, diabetes, and sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
  • Spiropiperidine Derivatives As Melanocortin Receptor Agonists

    view source
  • US Patent:
    6472398, Oct 29, 2002
  • Filed:
    Mar 20, 2001
  • Appl. No.:
    09/812339
  • Inventors:
    Brenda L. Palucki - Hillsborough NJ
    Ravi P. Nargund - East Brunswick NJ
  • Assignee:
    Merck Co., Inc. - Rahway NJ
  • International Classification:
    A61K 31496
  • US Classification:
    51425309, 544230, 544 6, 544 70, 5142278, 5142282, 5142285, 5142352, 5142372
  • Abstract:
    Certain novel spiropiperidine derivatives of structural formula Ia wherein the substituents are as defined herein are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
  • Substituted Piperidines As Melanocortin Receptor Agonists

    view source
  • US Patent:
    6767915, Jul 27, 2004
  • Filed:
    Jan 27, 2003
  • Appl. No.:
    10/343040
  • Inventors:
    Raman K. Bakshi - Edison NJ
    Khaled J. Barakat - Brooklyn NY
    Yingjie Lai - Edison NJ
    Ravi P. Nargund - East Brunswick NJ
    Brenda L. Palucki - Hillsborough NJ
    Min K. Park - Whippany NJ
    Iyassu K. Sebhat - New York NY
    Zhixiong Ye - Princeton NJ
    Arthur A. Patchett - Westfield NJ
  • Assignee:
    Merck Co., Inc. - Rahway NJ
  • International Classification:
    A61K 31445
  • US Classification:
    514325, 546203, 546205, 546202, 546199, 546198, 546194, 514330, 514324, 514322, 514318, 514326
  • Abstract:
    Certain novel 4-substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
  • Biaryl Substituted Triazoles As Sodium Channel Blockers

    view source
  • US Patent:
    7326726, Feb 5, 2008
  • Filed:
    Mar 12, 2004
  • Appl. No.:
    10/799230
  • Inventors:
    Prasun K. Chakravarty - Edison NJ, US
    Louis L. Zuegner III, legal representative - Flemington NJ, US
    Brenda Palucki - Hillsborough NJ, US
    Min K. Park - Whippany NJ, US
    William H. Parsons - Belle Mead NJ, US
    Bishan Zhou - Hoboken NJ, US
  • Assignee:
    Merck & Co., Inc. - Rahway NJ
  • International Classification:
    A61K 31/41
    C07D 249/08
  • US Classification:
    514359, 5482694
  • Abstract:
    Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier.
  • Piperazine Urea Derivatives As Melanocortin-4 Receptor Agonists

    view source
  • US Patent:
    7414057, Aug 19, 2008
  • Filed:
    Sep 5, 2003
  • Appl. No.:
    10/526178
  • Inventors:
    Raman Kumar Bakshi - Edison NJ, US
    Ravi P. Nargund - East Brunswick NJ, US
    Brenda L. Palucki - Hillsborough NJ, US
    Min K. Park - Whippany NJ, US
    Zhixiong Ye - Princeton NJ, US
  • Assignee:
    Merck & Co., Inc. - Rahway NJ
  • International Classification:
    C07D 401/12
    C07D 403/12
    A61K 31/453
    A61K 31/4545
    A61P 3/04
    A61P 3/10
  • US Classification:
    51425213, 544360
  • Abstract:
    Certain novel piperazine urea derivatives are agonists of the human melanocortin-4 receptor (MC-4R) and, in particular, are receptor-subtype selective agonists of MC-4R. They are useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity and diabetes.
  • Substituted Triazoles As Sodium Channel Blockers

    view source
  • US Patent:
    7459475, Dec 2, 2008
  • Filed:
    Nov 10, 2004
  • Appl. No.:
    10/985592
  • Inventors:
    Min K. Park - Whippany NJ, US
    Prasun K. Chakravarty - Edison NJ, US
    Bishan Zhou - Hoboken NJ, US
    Edward Gonzalez - Iselin NJ, US
    Hyun Ok - Colonia NJ, US
    Brenda Palucki - Hillsborough NJ, US
    William H. Parsons - Belle Mead NJ, US
    Rosemary Sisco - Old Bridge NJ, US
  • Assignee:
    Merck & Co. Inc. - Rahway NJ
  • International Classification:
    A61K 31/41
    C07D 249/08
  • US Classification:
    514383, 5482622
  • Abstract:
    Substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, migraine, headache pain, migraine headache, epilepsy, irritable bowel syndrome, diabetic neuropathy, multiple sclerosis, manic depression and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier.

Get Report for Brenda Lynn Palucki from Collegeville, PA, age ~53
Control profile